[이데일리 유진희 기자]We collected global pharmaceutical and bio industry issues for the week (February 19th to February 25th). This week, news related to hyperlipidemia and rheumatoid arthritis received industry attention. (Photo = Getty Images)
Research results have shown that finasteride (product name: Propecia, Proscar), a treatment for hair loss and benign prostatic hyperplasia, is effective in treating hyperlipidemia by lowering blood cholesterol levels.
Medical news portal News Medical Life Science reported that a research team led by Professor Jaume Hamengual of Food and Nutrition at the University of Illinois College of Agriculture disclosed these research results.
This is the result of analyzing data from 4,800 people (2009-2016), including 150 participants in the National Health and Nutrition Examination Survey (NHNES) who were taking finasteride. Among these, finasteride users had an average of 30 mg/dl lower total blood cholesterol levels than non-users. Low-density lipoprotein cholesterol levels were also low.
The research team also conducted experiments on mice to reconfirm this. This is done by administering different doses of finasteride to male mice that have been genetically modified to have an increased risk of arteriosclerosis. In addition, they were fed a high-fat, high-cholesterol diet for 12 weeks.
As a result, only the mice administered the highest dose of finasteride had lower blood cholesterol and atherosclerotic plaque levels. In mice administered finasteride, the liver inflammatory pathway was suppressed and the bile acid metabolism, oxidative phosphorylation (OP), and cholesterol pathways that help decompose fat were activated.
In the future, the research team plans to track the blood cholesterol levels of finasteride users or confirm the effectiveness of finasteride through clinical trials. The results of this study were published in the latest issue of the Journal of Lipid Research, an academic journal of the American Society for Biochemistry and Molecular Biology (ASBMB).
Research results have also shown that abatacept (product name: Orencia), a treatment for rheumatoid arthritis, is also effective in preventing rheumatoid arthritis. HealthDay News reported that Dr. Andrew Cope’s research team at the Rheumatic Disease Center at King’s College London (KCL) Medical School in the UK announced this fact.
These are the results of a clinical trial conducted on 213 patients (age 18 or older) at high risk of rheumatoid arthritis. They all had initial symptoms such as joint pain, but their joints were not swollen, so they were not diagnosed with rheumatoid arthritis.
They were divided into two groups and each received abatacept and placebo by intravenous injection once a week for one year. During the medication period, the abatacept group showed almost no symptoms or signs of rheumatoid arthritis compared to the control group. Pain, joint function, and quality of life scores also improved, and joint inflammation detected by ultrasound decreased.
One year after discontinuation of medication, approximately 6% of the abatacept group and 29% of the control group developed rheumatoid arthritis. Two years later, 25% and 37%, respectively, were diagnosed with rheumatoid arthritis. Side effects included upper respiratory infection, dizziness, nausea, and diarrhea. However, it was not a cause for concern. The results of this study were published in the latest issue of the British medical journal The Lancet.
ⓒComprehensive economic information media Edaily – Commercial reproduction and redistribution prohibited
2024-02-25 14:55:00
#Finasteride #hyperlipidemia #effect #Avatacept #arthritis #prevention클릭 #글로벌제약 #바이오
